The case for & against
Bull & Bear analysis
Bullish
Biotricity, Inc. (NASDAQ: BTCY) is a promising leader in the healthcare technology sector, focusing on innovative cardiac monitoring and management solutions, particularly through its advanced AI capabilities. Positioned within a rapidly growing market responding to the increasing demand for chronic disease management, Biotricity aims to enhance patient outcomes while optimizing healthcare resources. The company has strategically formed partnerships with Group Purchasing Organizations (GPOs) that provide access to a significant portion of U.S. hospitals, strengthening its position within the cardiac health technology ecosystem.
Bull says
- ↑Q1 2026 revenue $3.9M (21% YoY); achieved $333K positive EBITDA
- ↑Gross margin 81.5%; 87% of sales from recurring Tech-as-a-Service
- ↑GPO contracts cover ~90% of U.S. hospitals, boosting market penetration
- ↑Regulatory approvals in Canada and Saudi Arabia; 20–30% revenue upside
- ↑AI-driven platform enhances diagnostic accuracy and patient outcomes
- ↑Positive revision trends and potential share buybacks support momentum
Bear says
- ↓Net loss narrowed to $754K but earnings yield remains negative
- ↓Weak profitability metrics; rising interest costs strain margins
- ↓Growth factor declined amid intensifying cardiac tech competition
- ↓Dependence on GPO partnerships creates revenue concentration risk
- ↓International expansion faces regulatory hurdles and execution challenges
- ↓Elevated volatility and leverage risk highlight capital structure vulnerabilities
Earnings Call · Q1 2025 · Mgmt. Guidance
Updated 09-07-2026bullish
Transcript signals
Bull points
- Our recurring revenue generated from our technology as a service subscription model, as well as our usage-based subscriptions, remains robust, driven by the popularity of our FDA-cleared cardiac monitoring devices, BioCore and BioFlux. We anticipate further revenue growth in coming quarters as a result of our latest flagship device being a best-in-class device that is geared towards use in hospitals and large clinics where we are continuing to penetrate effectively.
- For the fourth quarter ended March 31, 2025, revenue increased by 16.5% year over year to $3.7 million. For the fiscal year, revenue rose by 14.3% to $13.8 million compared to $12.1 million in the prior year, which is a testament to the efficacy of our strategic initiatives and our focus on transitioning customers to a flat fee subscription-based model.
- Gross profit for the quarter totaled $3 million, up 31% from $2.3 million of the prior year period, attributed to the expansion of our recurring technology fee revenue base, efficiencies gained through proprietary AI, and improvements in our monitoring cost structure. Our gross margin was 80.4%, an improvement of over 890 basis points compared to 71.5% in the same quarter of the prior year.
Bear points
- This resulted in an improvement in our loss from operations of $5.7 million. Net loss attributable to common stockholders for the fiscal year ended March 31, 2025 was $11.9 million compared to a net loss of 14.9 million during the prior fiscal year.
- For the fourth quarter, net loss decreased to $2 million, despite the expenses associated with growth and rising variable interest rates.
Read full transcript analysis ›